NCT04858243

Brief Summary

Men in sub-Saharan Africa who test HIV-positive continue to have poor ART initiation and retention outcomes. The proposed project will test a home-based ART intervention for men who are living with HIV compared to facility-based ART. Findings will provide essential information on how to best reach men across the testing and treatment continuum, a critical step to curbing the HIV epidemic.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
930

participants targeted

Target at P75+ for not_applicable hiv

Timeline
Completed

Started Aug 2021

Longer than P75 for not_applicable hiv

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 21, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 26, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

August 2, 2021

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

May 15, 2023

Status Verified

May 1, 2023

Enrollment Period

3.7 years

First QC Date

April 21, 2021

Last Update Submit

May 12, 2023

Conditions

Keywords

HIVMenHIV Self-TestingART InitiationART RetentionHome-Based careAntiretroviral TherapyViral SuppressionSub-Saharan AfricaMalawi

Outcome Measures

Primary Outcomes (1)

  • 6-month viral suppression among men living with HIV

    Proportion of HIV-positive men tested HIV-positive who have an undetectable viral load 6-months after initiating ART (a maximum of 12-months after enrolling in the study). Sourced by medical chart reviews.

    12 months

Secondary Outcomes (3)

  • ART Initiation

    6 months

  • ART Retention

    18 months

  • Proportion of female clients and men who self-report at least one adverse event

    18 months

Study Arms (2)

Facility-Based ART

ACTIVE COMPARATOR

Men escorted to nearest health facility for ART initiation and continuation.

Other: Facility-Based ART

Home-Based ART

EXPERIMENTAL

Home-based ART initiation and continuation provided for 3-months.

Other: Home-Based ART

Interventions

Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.

Home-Based ART

Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.

Facility-Based ART

Eligibility Criteria

Age15 Years+
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Male partner ≥15 years of age
  • No reported interpersonal violence (IPV) as defined by World Health Organization (WHO) with the above male partner in the past 12-months
  • Male partner ever tested HIV-positive
  • Male partner not currently engaged in ART services, defined as:
  • Tested HIV-positive ≥14 days and not on ART ≥14 days after testing HIV- positive;
  • ≥14 days late for the first four-week follow up appointment; or
  • Initiated ART but ≥60 days late for last ART appointment;
  • Male partner living inside the facility catchment area (defined as any area that Healthcare Workers (HCWs) from the study facility routinely visit for tracing purposes)

You may not qualify if:

  • Male partner \<15 years of age
  • Reported interpersonal violence (IPV) as defined by WHO with the above male partner in the past 12-months
  • Male partner never tested HIV positive
  • Male partner tested HIV-positive \<14 days ago
  • Male partner currently engaged in ART services, defined as:
  • Initiated ART \<14 days late for the first four-week follow up appointment
  • Initiated ART and \<60 days late for last ART appointment
  • Male partner living outside the facility catchment area (defined as any area that HCWs from the study facility routinely visit for tracing purposes)
  • ≥15 years of age
  • Tested HIV positive using Ministry of Health standard algorithm (Determine + Unigold)
  • Not currently engaged in ART services, defined as:
  • Tested HIV-positive ≥14 days and not on ART ≥14 days after testing HIV-positive;
  • ≥14 days late for the first four-week follow up appointment; or
  • Initiated ART but ≥60 days late for last ART appointment;
  • Has not taken ART in the past 7-days, as indicated by a point of care (POC) urine assay
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Partners in Hope

Lilongwe, Malawi

Location

Related Publications (3)

  • Hubbard J, Mphande M, Robson I, Balakasi K, Phiri K, Chikuse E, Thorp M, Phiri S, Choko AT, Cornell M, Coates T, Dovel K. Core components of male-specific person-centred HIV care: a qualitative analysis from client and healthcare worker perspectives in Malawi. BMJ Public Health. 2024 Dec 22;2(2):e001100. doi: 10.1136/bmjph-2024-001100. eCollection 2024 Dec.

  • Holland KN, Hubbard J, Mphande M, Robson I, Phiri K, Onoya D, Chikuse E, Dovel K, Choko A. Implementation of Male-Specific Motivational Interviewing in Malawi: An Assessment of Intervention Fidelity and Barriers to Scale-Up. medRxiv [Preprint]. 2024 Sep 26:2024.09.24.24314326. doi: 10.1101/2024.09.24.24314326.

  • Choko AT, Coates TJ, Mphande M, Balakasi K, Robson I, Phiri K, Phiri S, Kulich M, Sweat M, Cornell M, Hoffman RM, Dovel K. Engaging men through HIV self-testing with differentiated care to improve ART initiation and viral suppression among men in Malawi (ENGAGE): A study protocol for a randomized control trial. PLoS One. 2023 Feb 24;18(2):e0281472. doi: 10.1371/journal.pone.0281472. eCollection 2023.

MeSH Terms

Conditions

Acquired Immunodeficiency SyndromeMultiple Endocrine Neoplasia Type 1

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesMultiple Endocrine NeoplasiaEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsNeoplasms, Multiple PrimaryNeoplastic Syndromes, HereditaryGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of University of California Global Health Institute

Study Record Dates

First Submitted

April 21, 2021

First Posted

April 26, 2021

Study Start

August 2, 2021

Primary Completion

March 31, 2025

Study Completion

June 30, 2025

Last Updated

May 15, 2023

Record last verified: 2023-05

Locations